Company Overview of Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. engages in discovering and developing therapeutic RNAi drug candidates. Its product candidates include RTP801i-14, a siRNA molecule for the treatment of wet age-related macular degeneration and diabetic macular edema; AKIi-5, a siRNA molecule for the prevention of acute kidney injury/acute renal failure following major cardiac surgery; and AHLi-11, a siRNA molecule for the prevention of chemotherapy and noise-induced hearing loss. The company’s products also include QPI 1002 for the treatment of delayed graft function in kidney transplantation patients; and QPI 1007 for the treatment of ocular neuroprotection. It offers siRNA drug candidate pipeline for the treatm...
6501 Dumbarton Circle
Fremont, CA 94555
Founded in 1993
Key Executives for Quark Pharmaceuticals, Inc.
Senior Vice President of Strategy & Planning
Compensation as of Fiscal Year 2013.
Quark Pharmaceuticals, Inc. Key Developments
Biocon Limited Enters into License and Collaboration Agreement with Quark Pharmaceuticals
Dec 23 13
Biocon Limited and Quark Pharmaceuticals, Inc. have entered into a license and collaboration agreement for the development of siRNA, or small interfering RNA, based novel therapeutics. This collaboration will enable Biocon to co-develop, manufacture & commercialize QPI-1007, a novel siRNA drug candidate for ophthalmic conditions, for India and other key markets. Biocon will have access to Quark's innovative and proprietary siRNA technology platform that can be leveraged for the development of novel therapeutics for various unmet medical needs. QPI-1007 is being developed for ocular neuroprotection in NAION (non- arteritic anterior ischemic optic neuropathy) and acute angle closure glaucoma. An expert team of scientists from Quark and Biocon will jointly work on the development of QPI-1007, and the additional novel pipeline, leveraging the siRNA innovative technology.
Biocon and Quark Pharmaceuticals Collaborate to Develop Novel siRNA Based Therapeutics
Dec 18 13
Biocon Limited and Quark Pharmaceuticals, Inc. announced that they have entered into licensing & collaboration agreement for the development of a range of siRNA based nmovel therapeutics. This collaboration will enable biocon to co-develop, manufacture & commercialize QP1-1007, a novel siRNA drug candidate for opthalmic conditions, for india and other key markets. Biocon will have access to Quark's innovative and proprietary siRNA technology platform that can be leveraged for the development of novel therapeutics for various unmet medical needs.
SBI Holdings to Turn Quark Pharmaceuticals into Consolidated Subsidiary
Nov 15 12
SBI Holdings, Inc. announced that Quark Pharmaceuticals, Inc. turn into a consolidated subsidiary. Quark is to become a consolidated subsidiary as Quark and Q-SFM, Inc. and will execute an absorption-type merger in which Quark will be the surviving entity and Q-SFM as a special purpose company will be the entity that ceases to exist after the merger. Quark and Q-SFM each passed a resolution on November 15, 2012 to execute the merger.
Similar Private Companies By Industry
Recent Private Companies Transactions